Scholarlink

<p>22q11.2 deletion syndrome (22q11.2 DS) is the second most common cause of congenital heart disease. The American College of Medical Genetics and Genomics (ACMG) has recently recommended implementing non-invasive prenatal screening (NIPS) for 22q11.2 DS for all pregnant women. This study aims to assess the effectiveness of routine NIPS for screening 22q11.2 deletion in a cohort of 38,495 pregnancies from the general population. We conducted a retrospective analysis of 38,495 pregnant women who underwent NIPS at Longgang Maternal and Child Health Hospital in Shenzhen from December 2022 to March 2024. Chromosomal microarray analysis (CMA) was performed on fetuses and pregnant women identified as high-risk for 22q11.2 DS by NIPS, using amniotic fluid samples and the leukocyte cells, respectively. Of the 38,495 cases, 22 were identified as high risk for 22q11.2 deletion by NIPS. Of these, 17 underwent amniocentesis, and 5 refused prenatal diagnosis. Concordant results between CMA and NIPS were observed in 8 cases, giving a positive predictive value (PPV) of 47.06% (8/17). Nine fetuses did not show 22q11.2 deletion by CMA, although the mothers of three fetuses were identified as having a maternal 22q11.2 deletion. Follow-up on 5 cases without prenatal diagnosis revealed one postpartum case of congenital heart disease (ventricular septal defect and atrial septal defect), three cases that were terminated, and one case that continued with normal fetal development. Routine non-invasive prenatal screening for 22q11.2 deletion demonstrates practical clinical utility and provides valuable insights for identifying pregnant women at risk for 22q11.2DS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the effectiveness of routine noninvasive prenatal screening for CNVs in 22q11.2 region in a cohort of 38,495 pregnancies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Xiaoyi Cong,
  • Liang Hu,
  • Yuanyuan Pei,
  • Jiatong Zhong,
  • Jinshuang Song,
  • Lijuan Wen,
  • Tong Zhang,
  • Yanan Liu,
  • Weiqiang Liu

摘要

22q11.2 deletion syndrome (22q11.2 DS) is the second most common cause of congenital heart disease. The American College of Medical Genetics and Genomics (ACMG) has recently recommended implementing non-invasive prenatal screening (NIPS) for 22q11.2 DS for all pregnant women. This study aims to assess the effectiveness of routine NIPS for screening 22q11.2 deletion in a cohort of 38,495 pregnancies from the general population. We conducted a retrospective analysis of 38,495 pregnant women who underwent NIPS at Longgang Maternal and Child Health Hospital in Shenzhen from December 2022 to March 2024. Chromosomal microarray analysis (CMA) was performed on fetuses and pregnant women identified as high-risk for 22q11.2 DS by NIPS, using amniotic fluid samples and the leukocyte cells, respectively. Of the 38,495 cases, 22 were identified as high risk for 22q11.2 deletion by NIPS. Of these, 17 underwent amniocentesis, and 5 refused prenatal diagnosis. Concordant results between CMA and NIPS were observed in 8 cases, giving a positive predictive value (PPV) of 47.06% (8/17). Nine fetuses did not show 22q11.2 deletion by CMA, although the mothers of three fetuses were identified as having a maternal 22q11.2 deletion. Follow-up on 5 cases without prenatal diagnosis revealed one postpartum case of congenital heart disease (ventricular septal defect and atrial septal defect), three cases that were terminated, and one case that continued with normal fetal development. Routine non-invasive prenatal screening for 22q11.2 deletion demonstrates practical clinical utility and provides valuable insights for identifying pregnant women at risk for 22q11.2DS.